FIELD OF APPLICATION DETAILS
Generic Name
Bucetin
Active Ingredient
Bucetin
US Brand Names
Not Available
Drug Category
Nephrology
Drug Class
Palliative treatment, Immunosuppressive therapy
Dosage Forms
Tablet, Capsule
Route of Administration
Oral
FDA Approval Status
Not approved

Bucetin Overview

Bucetin (chemically designated as N-(4-ethoxyphenyl)-3-hydroxybutanamide; chemical formula C12H17NO3) is a synthetic, non-opioid anilide derivative possessing analgesic and antipyretic properties. Chemically, it belongs to the class of organic compounds known as anilides within the benzene and substituted derivatives sub-class of benzenoids. Structurally, it is closely related to phenacetin and paracetamol (acetaminophen), featuring a para-ethoxyphenyl group linked via an amide bond to a 3-hydroxybutanoyl fatty acyl chain.

In human pharmacotherapy, pain management, and nephrology, Bucetin functioned historically as a non-narcotic antipyretic and minor analgesic agent (ATC codes N02BE04 for bucetin and N02BE54/N02BE74 for combinations). Formulated primarily in oral combination products with other antipyretics or psycholeptics, it was indicated for the symptomatic relief of mild-to-moderate pain, headache, and fever. Approved for clinical use in select European nations such as Germany, it was voluntarily withdrawn from the market in 1986 following extensive clinical and epidemiological evidence linking chronic anilide consumption to severe renal papillary necrosis, interstitial nephritis, and analgesic nephropathy. Bucetin was never submitted or approved for medical distribution in the United States by the US FDA.

What Is Bucetin and How Does It Work?

Bucetin acts primarily through inhibition of central prostaglandin synthesis and modulation of central thermoregulatory centers, mediating antipyresis and central antinociception.

Its primary chemical, physiological, and analgesic mechanisms include:

  • Central Cyclooxygenase Inhibition: Like other anilide derivatives (such as phenacetin and acetaminophen), Bucetin inhibits central cyclooxygenase (COX) enzymes within the central nervous system, reducing prostaglandin E2 (PGE2) synthesis in the brain.
  • Thermoregulatory Resetting: By suppressing PGE2 accumulation in the preoptic area of the anterior hypothalamus, it resets the hypothalamic thermoregulatory set-point, promoting peripheral vasodilation, cutaneous blood flow, and sweating to dissipate body heat.
  • Peripheral & Central Pain Threshold Elevation: It elevates the pain perception threshold by inhibiting spinal and central nociceptive signal transduction pathways without binding to opioid receptors.
  • Metabolic Conversion to Active Intermediates: Following oral ingestion, Bucetin undergoes hepatic biotransformation via O-deethylation and amide hydrolysis, producing reactive phenetidine metabolites capable of binding cellular macromolecules.
  • Renal Tubular Toxicity Mechanism: Reactive metabolites generate oxidative stress, lipid peroxidation, and covalent binding within renal medullary tubular cells, causing metabolic exhaustion, ischemia, and renal cell death.

Is Bucetin FDA Approved?

Bucetin has never been approved for marketing or pharmaceutical distribution in the United States by the US FDA, classifying its current approval status as Not Approved.

What Was Bucetin Used For?

  • Historical symptomatic treatment of mild-to-moderate pain, including headaches, toothaches, myalgias, and neuralgias.
  • Historical antipyretic management of fever associated with viral or bacterial infections.
  • Historical inclusion in fixed-dose combination analgesics alongside caffeine, barbiturates, or other antipyretics.

Before Taking Bucetin: Contraindications & Precautions

Bucetin has been withdrawn from clinical use globally due to severe organ toxicity and must not be administered. When utilized historically, it was contraindicated in patients with pre-existing renal impairment, chronic kidney disease, severe hepatic dysfunction, glucose-6-phosphate dehydrogenase (G6PD) deficiency, or known hypersensitivity to anilide analgesics.

Who Should Not Take Bucetin?

  • Individuals with pre-existing renal disease, chronic kidney disease, or renal papillary necrosis.
  • Patients with severe hepatic impairment or active liver disease.
  • Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency (due to risk of hemolytic anemia and methemoglobinemia).
  • Individuals with known hypersensitivity to Bucetin, phenacetin, or acetaminophen.

Bucetin, Pregnancy & Safety

Preclinical and clinical safety data regarding Bucetin during pregnancy are severely limited. Anilide derivatives cross the placental barrier and can induce fetal methemoglobinemia, renal tubular injury, and maternal-fetal oxidative stress. Bucetin is not recommended for use during pregnancy or lactation.

Tell Your Doctor Before Taking Bucetin

Patients who previously consumed chronic over-the-counter combination analgesics should inform their nephrologist if they experience persistent flank pain, dark urine, fatigue, or unexplained elevations in serum creatinine.

Bucetin Dosage & Administration

Historically formulated as oral tablets or capsules, frequently in combination with secondary analgesic or sedative compounds.

Standard Bucetin Dosing

  • Historical Oral Analgesic Dosing (Adults): Administered historically as 250 mg to 500 mg orally every 4 to 6 hours as needed for pain or fever, strictly limited in duration to avoid cumulative renal exposure.

How Bucetin Was Administered

  • Administered orally with a full glass of water, typically after meals to mitigate potential gastric irritation.

Bucetin Clinical Efficacy & Safety Profile

While Bucetin demonstrated effective acute analgesic and antipyretic properties comparable to phenacetin, its chronic safety profile proved unacceptably dangerous. Prolonged or cumulative ingestion led directly to analgesic nephropathy, characterized by chronic tubulointerstitial nephritis, renal papillary necrosis, and progressive end-stage renal disease (ESRD). Furthermore, reactive metabolite formation posed risks of urothelial malignancies and hematological toxicity, leading health authorities in Germany and globally to withdraw the drug in 1986.

Bucetin Side Effects & Safety Profile

BLACK BOX WARNING

Bucetin has never been approved for medical use by the US Food and Drug Administration, and consequently, it does not carry an FDA-mandated Black Box Warning. This status reflects its lack of regulatory approval in the United States.

Common adverse effects included mild gastrointestinal upset, nausea, dizziness, and cutaneous rash. Serious adverse risks included severe analgesic nephropathy, renal papillary necrosis, chronic interstitial nephritis, acute renal failure, methemoglobinemia, hemolytic anemia, and urothelial carcinoma. Holds no FDA Black Box Warning due to unapproved status.

Common Bucetin Side Effects

  • Gastrointestinal & Dermatological: Nausea, vomiting, epigastric discomfort, heartburn, and mild allergic skin rash (urticaria).
  • Neurological: Transient dizziness, lightheadedness, and headache.

Serious Bucetin Adverse Events

  • Analgesic Nephropathy & Renal Papillary Necrosis: Irreversible destruction of renal medullary papillae and chronic interstitial fibrosis resulting from cumulative toxic metabolite accumulation.
  • Acute & Chronic Renal Failure: Progressive loss of glomerular filtration rate, oliguria, and development of end-stage renal disease (ESRD).
  • Hematological Toxicity: Methemoglobinemia (compromised oxygen-carrying capacity of hemoglobin) and drug-induced hemolytic anemia, particularly in G6PD-deficient individuals.
  • Urothelial Malignancies: Increased long-term incidence of transitional cell carcinoma of the renal pelvis and ureter following prolonged anilide abuse.

Managing Bucetin Side Effects

Because Bucetin is a withdrawn agent, management focuses on treating past cumulative nephrotoxicity. Patients showing signs of analgesic nephropathy require immediate drug cessation, adequate hydration, strict avoidance of nephrotoxic drugs, and management by a nephrologist.

Bucetin Drug Interactions & What to Avoid

Co-administration with other nephrotoxic or hepatotoxic medications increases systemic toxicity risks.

Bucetin Drug-Drug Interactions

  • Other Anilide Analgesics (e.g., Acetaminophen, Phenacetin): Additive nephrotoxic and hepatotoxic effects; increases risk of renal papillary necrosis and methemoglobinemia.
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Concurrent use markedly accelerates renal medullary ischemia and chronic kidney damage.
  • Hepatotoxic / P450-Inducing Agents (e.g., Rifampin, Phenobarbital): Increases production of reactive toxic metabolites, exacerbating tissue injury.

Bucetin, Food & Alcohol

Avoid alcohol consumption, as ethanol induces cytochrome P450 enzymes and depletes hepatic glutathione, drastically increasing the risk of toxic metabolite-induced organ injury.

Bucetin: Missed Dose, Overdose & Storage

Historical dosing was episodic for pain. Overdose causes severe liver and kidney necrosis. Store at controlled room temperature (15°C–25°C).

Missed Dose of Bucetin

Not applicable; historical administration was strictly on an as-needed basis for acute symptomatic relief.

Bucetin Overdose & Emergency

Acute overdose results in severe anilide toxicity characterized by cyanosis (secondary to severe methemoglobinemia), jaundice, acute hepatic necrosis, oliguric acute renal failure, confusion, and cardiovascular collapse. Emergency management requires gastric lavage, activated charcoal, N-acetylcysteine (NAC) administration, methylene blue for severe methemoglobinemia, and hemodialysis if acute renal failure occurs.

How to Store Bucetin

Store at controlled room temperature between 15°C and 25°C (59°F to 77°F). Protect from excessive heat, light, and moisture. Keep strictly out of reach of children.

Bucetin Patient Management & Monitoring

Requires routine renal function tracking, complete blood count, and urinalysis in patients with historical exposure.

Tests Before Starting Bucetin

Baseline serum creatinine, blood urea nitrogen (BUN), estimated glomerular filtration rate (eGFR), complete blood count (CBC), liver function tests, and baseline urinalysis.

Monitoring During Bucetin Treatment

Monitoring renal function parameters (BUN, creatinine, eGFR); checking urinalysis for sterile pyuria, hematuria, or proteinuria; monitoring hemoglobin and methemoglobin levels if cyanosis develops.

Bucetin Do’s and Don’ts

  • Do consult a physician for modern, safe, FDA-approved non-opioid pain relievers.
  • Do seek immediate medical evaluation if you have a history of chronic combination analgesic use and develop dark urine or flank pain.
  • Do not take Bucetin under any circumstances due to its global market withdrawal.
  • Do not combine over-the-counter pain relievers without medical supervision.

Frequently Asked Questions

What exact type of chemical is Bucetin?

Bucetin is a synthetic, non-opioid anilide derivative that belongs to the class of organic compounds known as anilides within the benzene and substituted derivatives sub-class of benzenoids. Structurally related to phenacetin and paracetamol, it features a para-ethoxyphenyl group linked via an amide bond to a 3-hydroxybutanoyl fatty acyl chain.

How did Bucetin function as an analgesic and antipyretic agent?

Bucetin functioned through central antinociceptive and antipyretic mechanisms that provided symptomatic relief of mild-to-moderate pain, headache, and fever. Following oral administration, its active compound mediated central pain threshold elevation and hypothalamic thermoregulatory resetting to facilitate body heat dissipation.

Is Bucetin FDA approved in the United States?

No, Bucetin has never been approved for marketing or pharmaceutical distribution in the United States by the US FDA, making its official approval status Not Approved.

Why was Bucetin withdrawn from the market?

Bucetin was voluntarily withdrawn from the market in 1986 following clinical and epidemiological evidence linking its chronic consumption to severe renal toxicity. Prolonged use was associated with renal papillary necrosis, interstitial nephritis, and chronic analgesic nephropathy.

What were the primary dosage forms and historical routes of administration for Bucetin?

Bucetin was formulated for oral administration as tablets and capsules. It was primarily distributed in select European nations, frequently as part of fixed-dose oral combination products with other antipyretic or psycholeptic agents.

Does Bucetin carry an FDA Black Box Warning?

No, Bucetin does not carry an FDA Black Box Warning because it was never submitted or approved for medical use by the US FDA.

What precautions were associated with historical Bucetin use?

Bucetin was contraindicated in individuals with pre-existing renal impairment, liver dysfunction, or a history of hypersensitivity to anilide derivatives. Co-administration with other potentially hepatotoxic or nephrotoxic agents was avoided due to the increased risk of severe organ toxicity.

References

  • DrugBank Database – Bucetin Clinical Profile (DB13278)
  • Classyfire Database – Anilides / Benzenoids Taxonomy Profile
  • German Federal Institute for Drugs and Medical Devices (BfArM) – Drug Withdrawal Records (1986)

The detailed medical and chemical information provided on this specific web page is intended strictly for educational and informational purposes regarding complex pharmacological mechanisms. It absolutely does not constitute professional medical advice, medical diagnosis, or specific treatment recommendations. Always consult a licensed healthcare provider before making any personal decisions regarding complex medical conditions, medication adjustments, or dietary changes.